Skip to main content
. 2021 Dec 30;19:1–11. doi: 10.1016/j.bioactmat.2021.12.018

Fig. 4.

Fig. 4

a, Intracellular GSH levels in MCF-7/ADR cells treated with different formulations (MNP, PMNP, PMNP-DOX and PMNP-DOX@RBC); n = 3. b, Cell viability in the presence of apoptosis inhibitor, necroptosis-specific inhibitor, and autophagy inhibitor, ferroptosis inhibitor, respectively. c, Flow cytometry analysis of MCF-7/ADR cells lipid ROS production evaluated using C11-BODIPY probes. d, Representative confocal fluorescence microscopy images of LPO. Staining assay of MCF-7/ADR cells via C11-BODIPY staining. Western blot analysis of the expression of key ferroptosis makers, including GPX4 (e), NOX4(f), and P-gp (f) in MCF-7/ADR cells treated with different formulations.